LogicBio Therapeutics, Inc. (NASDAQ:LOGC) was founded in 2014 and is headquartered in Cambridge, Massachusetts, with 20 full-time employees (7/30/2018). It is a genome editing company that focuses on the development of drugs and uses our proprietary The technology platform GeneRide provides durable treatment of rare diseases for patients with severe unmet medical needs.
LogicBio Therapeutics (LOGC):
LogicBio Therapeutics’ GeneRide technology aims to accurately integrate corrective genes into the patient’s genome to provide stable therapeutic effects. Because GeneRide is designed to have this long-lasting therapeutic effect, we initially targeted rare liver diseases in pediatric patients, where it is essential to provide treatment in the early stages of the patient before irreversible disease pathology occurs.
LogicBio Therapeutics has demonstrated the company’s proof of concept for its therapeutic platform in many animal models of diseases, and is focusing on the development of its main product candidate LB-001-for the treatment of methylmalonic acidemia (MMA), which is An inherited, life-threatening disease.
GeneRide is LogicBio Therapeutics’ genome editing technology, which uses homologous recombination (HR), a naturally occurring DNA repair process, to maintain the fidelity of the genome. The company believes that by using HR, GeneRide will make it possible to insert therapeutic genes (called transgenes) into specific target genome locations without the use of exogenous nucleases (exogenous nucleases are enzymes used to cut DNA) . GeneRide targeted transgene integration is designed to utilize these targeted endogenous promoters to drive high levels of tissue-specific gene expression without the harmful problems associated with the use of exogenous promoters.
LogicBio Therapeutics developed GeneRide using certain core technologies authorized by Stanford University and the University of Texas.
Based on GeneRide technology, LogicBio Therapeutics is developing our main product candidate LB-001 to treat MMA (methylmalonic acidemia). The company expects to submit an IND (New Drug Application) and initiate phase I/II clinical trials of LB-001 before the end of 2019. The company believes that the clinical evidence of concepts obtained in inherited liver diseases (such as MMA) will validate its platform technology, including its potential applications in other organs and diseases.
In addition to MMA, LogicBio Therapeutics has demonstrated its platform’s proof of concept in animal disease models for hemophilia B, α-1-antitrypsin deficiency (A1ATD) and Crigler-Najjar syndrome. The company expects to select future product candidates from these genetic diseases, either by targeting the original liver, or by targeting the central nervous system or muscle.
LogicBio Therapeutics (LOGC) investment:
LogicBio Therapeutics, Inc. (NASDAQ:LOGC) submitted its IPO prospectus on 9/25/2018, and plans to land on Nasdaq on 10/19/2018. The issue price is US$12.00-14.00, and 5.77 million shares will be issued. Over $92,897,000.00, underwriting by Jefferies/ Barclays/ William Blair.